Literature DB >> 32369240

Cutaneous manifestations of a 21st century worldwide fungal epidemic possibly complicating the COVID-19 pandemic to jointly menace mankind.

Robert A Schwartz1, Rajendra Kapila1.   

Abstract

In view of the new viral COVID-19 pandemic, the fungal Candida auris epidemic still in progress worldwide highlights non-Candida albicans candidal infections. We describe an immunocompetent woman with a cutaneous manifestation of Candida parasilopsis fungemia, a prominent eschar, which proved to be the nidus for the candidemia. We stress the value of selectively removing eschars. C. parasilopsis and C. auris are increasingly important causes of sepsis and wound infections. We emphasize that commercially available biochemical-based tests may misidentify C. auris as C. parapsilosis, and stress the added danger of C. auris to critically ill-hospitalized COVID-19 patients. Any health care facility with evidence of infection or colonization with C. auris requires very close monitoring, since this fungus is a nosocomial threat comparable to SARS-CoV-2 in its mortality and fomite adhesiveness! Both organisms have the potential to be transmitted as nosocomial pathogens; health care workers need to follow strict CDC guidelines. During this COVID-19 pandemic, every health care facility should closely monitor for the possible deadly combination of the SARS-CoV-2 and C. auris. The identification of C. auris necessitates use of sophisticated technology not readily available to make this essential diagnosis since C. auris is multi-drug resistant and isolation precautions would become paramount.
© 2020 Wiley Periodicals LLC.

Entities:  

Keywords:  Candida; Candida auris; Candida parasilopsis; SARS-CoV-2; coronavirus disease 2019 (COVID-19); eschar; nosocomial infection; sepsis

Mesh:

Year:  2020        PMID: 32369240     DOI: 10.1111/dth.13481

Source DB:  PubMed          Journal:  Dermatol Ther        ISSN: 1396-0296            Impact factor:   2.851


  4 in total

1.  Public health issues with Candida auris in COVID-19 patients.

Authors:  Edmund J Janniger; Rajendra Kapila
Journal:  World Med Health Policy       Date:  2021-09-16

2.  COVID-19 with dermatologic manifestations and implications: An unfolding conundrum.

Authors:  Nawaf Almutairi; Robert A Schwartz
Journal:  Dermatol Ther       Date:  2020-07-01       Impact factor: 3.858

Review 3.  Disseminated intravascular coagulation: A devastating systemic disorder of special concern with COVID-19.

Authors:  Parmvir Singh; Robert A Schwartz
Journal:  Dermatol Ther       Date:  2020-09-04       Impact factor: 3.858

Review 4.  Azithromycin and COVID-19: Prompt early use at first signs of this infection in adults and children, an approach worthy of consideration.

Authors:  Robert A Schwartz; Robert M Suskind
Journal:  Dermatol Ther       Date:  2020-07-12       Impact factor: 3.858

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.